| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PYCRL |
| Uniprot No | Q53H96 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-274aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMAAAEPS PRRVGFVGAG RMAGAIAQGL IRAGKVEAQH ILASAPTDRN LCHFQALGCR TTHSNQEVLQ SCLLVIFATK PHVLPAVLAE VAPVVTTEHI LVSVAAGVSL STLEELLPPN TRVLRVLPNL PCVVQEGAIV MARGRHVGSS ETNLLQHLLE ACGRCEEVPE AYVDIHTGLS GSGVAFVCAF SEALAEGAVK MGMPSSLAHR IAAQTLLGTA KMLLHEGQHP AQLRSDVCTP GGTTIYGLHA LEQGGLRAAT MSAVEAATCR AKELSRK |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PYCRL(吡咯啉-5-羧酸还原酶样蛋白)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Structural and functional characterization of recombinant human PYCRL and its role in cancer cell proliferation"*
**作者**: Zhang Y, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组人源PYCRL蛋白，通过X射线晶体学解析其三维结构，发现其与脯氨酸代谢通路相关。实验表明PYCRL在多种癌细胞中高表达，敲低后显著抑制肿瘤细胞增殖，提示其可能作为癌症治疗靶点。
---
2. **文献名称**: *"PYCRL regulates proline metabolism to drive collagen synthesis and tumor fibrosis"*
**作者**: Wang L, et al.
**摘要**: 利用重组PYCRL蛋白进行体外酶活分析，发现其催化脯氨酸前体合成的关键作用。体内实验显示PYCRL通过调控胶原蛋白生成促进肿瘤微环境纤维化，为靶向代谢途径的抗癌策略提供依据。
---
3. **文献名称**: *"Development of a high-throughput screening assay for PYCRL inhibitors using recombinant protein"*
**作者**: Gupta S, et al.
**摘要**: 研究构建了基于重组PYCRL蛋白的高通量筛选平台，筛选出多个小分子抑制剂，并通过功能实验验证其抑制酶活性和抗肿瘤效果。该方法为开发PYCRL靶向药物奠定基础。
---
注：以上文献为示例性内容，实际文献需通过PubMed或Web of Science等数据库检索。若需具体文章，建议以“PYCRL recombinant protein”、“PYCRL proline metabolism”为关键词进一步查询。
PYCRL (Pyrroline-5-Carboxylate Reductase-Like) is a member of the pyrroline-5-carboxylate reductase (PYCR) enzyme family, which plays a critical role in proline biosynthesis. Proline, a multifunctional amino acid, is essential for protein structure, cellular redox balance, and stress response. PYCRL catalyzes the final step of proline synthesis by reducing pyrroline-5-carboxylate (P5C) to proline using NAD(P)H as a cofactor. Unlike its mitochondrial counterparts PYCR1 and PYCR2. PYCRL is localized in the cytoplasm and exhibits distinct substrate preferences, suggesting functional divergence within the family.
Recombinant PYCRL protein is engineered through heterologous expression systems, such as *E. coli* or mammalian cell cultures, to enable biochemical and structural studies. Its production involves cloning the PYCRL gene into expression vectors, optimizing conditions for high-yield synthesis, and purifying the protein via affinity chromatography. The recombinant form retains enzymatic activity, allowing researchers to investigate its kinetic properties, regulatory mechanisms, and interactions with metabolic pathways.
PYCRL has garnered attention for its potential roles in cancer, neurodegeneration, and metabolic disorders. Dysregulation of proline metabolism, linked to PYCRL activity, is observed in tumors, where proline supports rapid proliferation and stress adaptation. Recombinant PYCRL facilitates drug discovery by serving as a target for inhibitors aimed at disrupting cancer-specific metabolism. Additionally, studies explore its involvement in aging and oxidative stress resistance, leveraging recombinant protein to dissect molecular pathways. As a tool, PYCRL recombinant protein bridges basic research and therapeutic development, offering insights into metabolic adaptability and disease mechanisms.
×
